ACRUX LIMITED — Board/Management Information 2021

Jun 20, 2021

==> picture [83 x 79] intentionally omitted <==

ASX Release

Change in Company Secretary

Melbourne, Australia; 21 June 2021: Acrux Limited (ASX:ACR, “ Acrux ”) advises that Joanna Johnson has been appointed to the role of Chief Financial Officer and Company Secretary, effective 21 June 2021. Joanna replaces Deborah Ambrosini who will leave the Company on 25 June 2021.

Joanna is a Chartered Accountant. She has a strong history in pharmaceuticals and is experienced in commercial environments, supporting manufacturing, distribution, product development as well as sales and business development. Her previous roles included significant senior finance roles within the pharmeutical industry with responsibility for the Asia Pacific region. She is an experienced CFO and Company Secretary in both privately owned and ASX listed pharmaceutical companies.

We welcome Joanna to the Acrux senior management team and thank Deborah for her contribution to Acrux.

Authorised by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis Acrux Limited CEO & Managing Director P: + 61 3 8379 0100 E: michael.kotsanis@acrux.com.au

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au